Source: International Congress 2014 – Combination therapy in pulmonary arterial hypertension (PAH): the evidence grows
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Sitbon (Le Kremlin-Bicêtre, France). Upfront combination PAH therapy in severe PAH. International Congress 2014 – Combination therapy in pulmonary arterial hypertension (PAH): the evidence grows

Member's Comments

No comment yet.

Related content which might interest you: Long-term sitaxsentan therapy in PAH Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004 Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension Source: Eur Respir J, 57 (1) 2001120; 10.1183/13993003.01120-2020 Year: 2021 Dipyridamol as adjuvant therapy in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005 Emerging therapies in PAH and scleroderma-related PAH Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension Year: 2008 Combination therapy with sotatercept analog RAP-011 is superior to sildenafil alone in severe experimental PAH and RAP-011 benefits persist after treatment cessation Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020 Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 563s Year: 2003 A matched pairs analysis of long-term outcomes in first-line i.v. epoprostenol or first-line bosentan treated idiopathic pulmonary arterial hypertension Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010 The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study Source: Eur Respir J 2014; 43: 1691-1697 Year: 2014 Combination therapy with sildenafil and sitaxentan therapy for pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008 Efficacy and toxicity of azathioprine plus corticosteroids in 32 patients with chronic persistent sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 712s Year: 2004 Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease Source: Eur Respir J 2004; 24: Suppl. 48, 280s Year: 2004 Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients Source: Eur Respir Rev 2013; 22: 93-95 Year: 2013 Idiopathic pulmonary fibrosis: efficacy of complex immunosuppressive therapy by cyclophosphamide and corticosteroids Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010